A federally funded research team led by Sheri Holmen, PhD, investigator at Huntsman Cancer Institute and professor in the ...

Information on the survival of urothelial cancer (UCa) patients with brain metastases (BM) is largely unreliable due to the rarity of such cases. Previous studies that have attempted to capture the ...

NEW YORK - A Ludwig Cancer Research study has identified a key barrier to the efficacy of a promising combination of ...

2025 — A new study shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study suggests ... Jan. 14, 2025 — Researchers have ...

“Once melanoma has spread to the brain, it’s very hard to treat. Metastasis to the brain is one of the main causes of death from melanoma,” says Holmen. “We wanted to find a solution to an unmet ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

A novel intranasal drug delivery system for brain tumors is advancing clinical trials in India, offering a non-invasive, ...

From: Susan Gallien ...

“Once melanoma has spread to the brain, it’s very hard to treat. Metastasis to the brain is one of the main causes of death from melanoma,” says Holmen. “We wanted to find a solution to an unmet ...